Cecile Michel
Overview
Explore the profile of Cecile Michel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guigay J, Le Caer H, Ferrand F, Geoffrois L, Saada-Bouzid E, Fayette J, et al.
Lancet Healthy Longev
. 2024 May;
5(6):e392-e405.
PMID: 38759667
Background: A standard treatment for fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME trial, few...
2.
Gourmelon A, Hubert P, Grignard E, Baumann L, Munn S, Michel C
ALTEX
. 2024 Mar;
41(3):395-401.
PMID: 38501278
The 4th Annual Forum on Endocrine Disrupters organized by the European Commission brought together the authors of this article around the topic: “From bench to validated test guidelines: (pre)validation of...
3.
Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky M, et al.
Lancet Healthy Longev
. 2024 Mar;
5(3):e182-e193.
PMID: 38432247
Background: At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and...
4.
Bolling A, Mallock N, Zervas E, Caille-Garnier S, Mansuy T, Michel C, et al.
Tob Prev Cessat
. 2022 Jul;
8:28.
PMID: 35860505
The Tobacco Products Directive (TPD) defines enhanced reporting obligations applying to 15 priority additives added to cigarettes and roll-your-own tobacco. A consortium of 12 international tobacco companies submitted 14 reports...
5.
Havermans A, Mallock N, Zervas E, Caille-Garnier S, Mansuy T, Michel C, et al.
Tob Prev Cessat
. 2022 Jul;
8:27.
PMID: 35860504
The European Union Tobacco Products Directive (EU TPD) mandates enhanced reporting obligations for tobacco manufacturers regarding 15 priority additives. Within the Joint Action on Tobacco Control (JATC), a review panel...
6.
Guseva Canu I, Gaillen-Guedy A, Antilla A, Charles S, Fraize-Frontier S, Luce D, et al.
Occup Environ Med
. 2022 May;
PMID: 35501125
Objectives: Animal bioassays have demonstrated convincing evidence of the potential carcinogenicity to humans of titanium dioxide (TiO), but limitations in cohort studies have been identified, among which is the healthy...
7.
Printemps N, Magueresse-Battistoni B, Mhaouty-Kodja S, Viguie C, Michel C
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328575
This review provides an overview of the assessment of the endocrine disrupting (ED) properties of carbon disulfide (CS), following the methodology used at the European level to identify endocrine disruptors....
8.
Serra H, Beausoleil C, Habert R, Minier C, Picard-Hagen N, Michel C
Environ Health Perspect
. 2019 Oct;
127(10):106001.
PMID: 31617754
Background: The substitution of bisphenol A (BPA) by bisphenol B (BPB), a very close structural analog, stresses the need to assess its potential endocrine properties. Objective: This analysis aimed to...
9.
Guseva Canu I, Fraize-Frontier S, Michel C, Charles S
J Expo Sci Environ Epidemiol
. 2019 Aug;
30(3):430-435.
PMID: 31420585
We address here the importance of epidemiological evidence in risk assessment and decision-making in Europe. To illustrate this, titanium dioxide (TiO) was used as a model compound. TiO is widely...
10.
Guigay J, Saada-Bouzid E, Peyrade F, Michel C
Curr Treat Options Oncol
. 2019 Jun;
20(8):65.
PMID: 31240480
For most of patients with a recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), the treatment remains palliative: The main objective is to reduce the symptoms related to the...